Advertisement
YOU ARE HERE: LAT HomeCollectionsUpjohn Co
IN THE NEWS

Upjohn Co

FEATURED ARTICLES
NEWS
October 3, 1991 | WILLIAM TUOHY and MARLENE CIMONS, TIMES STAFF WRITERS
The British government on Wednesday banned the drug Halcion, the world's most widely prescribed sleeping pill. Halcion, and other medicines containing triazolam, have been associated with psychological side effects, particularly memory loss and depression, an announcement from the Department of Health said.
ARTICLES BY DATE
NEWS
September 28, 1999 | TERENCE MONMANEY, TIMES MEDICAL WRITER
The current New England Journal of Medicine--one of the world's top outlets of clinical information--carries a favorable article on two popular hair-loss treatments without disclosing the author's financial ties to the companies that make the drugs. Publication of the article, by Dr. Vera Price, a UC San Francisco professor of clinical dermatology, raises questions about the journal's monitoring of potential conflicts of interest.
Advertisement
BUSINESS
February 23, 1990 | United Press International
The board of directors of the Upjohn Co. has approved formation of Upjohn Laboratories, a new corporate entity that combines the company's pharmaceutical research and medical functions. The board has also elected Jerry R. Mitchell, formerly vice president for pharmaceutical research, to be senior vice president and president of Upjohn Laboratories.
BUSINESS
October 18, 1995 | Times Staff and Wire Reports
Upjohn Stockholders OK Merger With Pharmacia: Upjohn Co. stockholders approved a merger with Swedish drug maker Pharmacia, as expected, moving the proposed combination one step closer to completion. Separately, Upjohn reported third-quarter income from continuing operations rose 4% to $133 million as sales grew 3% to $831 million from the 1994 quarter.
BUSINESS
July 17, 1990 | United Press International
Upjohn Co. said today that its second-quarter earnings jumped 21% from last year, while sales for the period rose 11%. The pharmaceutical giant said it earned $114.1 million, or 62 cents a share, from continuing operations in the second quarter vs. $94.6 million, or 51 cents a share, in the same quarter in 1989.
BUSINESS
April 15, 1993 | From Times Staff and Wire Reports
Upjohn Chairman's Condition Deteriorates: Upjohn Co. said Theodore Cooper, its ailing chairman and chief executive, has been moved to an intensive care ward because his bone cancer brought on "a sudden deterioration" in his health. At a special meeting, the pharmaceutical giant's board of directors elected Ley S. Smith to the position of president and chief operating officer.
BUSINESS
April 26, 1993 | From Times Staff and Wire Reports
Upjohn Names Acting CEO: Ley Smith has been appointed acting chief executive officer of Upjohn Co. following the death of Chairman and Chief Executive Theodore Cooper. Cooper, who in January was diagnosed with bone marrow cancer, died Thursday. He was 64 and had been Upjohn's chairman since 1987. Smith, 58, the pharmaceutical company's president and chief operating officer, joined Upjohn as a salesman in 1958.
BUSINESS
August 22, 1995 | From Associated Press
It sounds like simple economics. As drug companies continue their merger frenzy, there will be less competition, resulting in less innovation and higher prices for consumers, right? Not necessarily, say industry watchers, who point out that other factors, such as the growth of health maintenance organizations and the public's demand for more non-prescription medicines, continue to push prices downward. Sunday's $13-billion proposed linkup of Sweden's Pharmacia and the United States' Upjohn Co.
NEWS
August 21, 1995 | PATRICK LEE, TIMES STAFF WRITER
In a deal that would create the world's ninth-largest drug company, U.S. pharmaceutical giant Upjohn Co. and Sweden's Pharmacia AB said Sunday that they will merge in an exchange of stock valued at $13 billion. The planned merger, which would result in a company with $7 billion in annual revenue, is the latest in a series of consolidations sweeping the industry as concern about high health-care costs forces drug companies to seek economies of scale. Upjohn, based in Kalamazoo, Mich.
BUSINESS
July 7, 1995 | From Associated Press
Men will soon be able to buy the first government-sanctioned drug to relieve sexual impotence. The Food and Drug Administration approved Caverject on Thursday, and manufacturer Upjohn Co. said the drug will be in pharmacies by September. It is available by prescription only; a price has not been set. When injected into the penis, the drug can induce an erection within five to 20 minutes in up to 80% of cases, the FDA said.
BUSINESS
December 29, 1994 | From Associated Press
Tests on humans of a drug considered crucial to Upjohn Co.'s future have been suspended because of unexplained deaths among some American patients, the company announced Wednesday. Upjohn, based in Kalamazoo, Mich., said it suspended the clinical trials of the drug Freedox for treatment of head injuries on the recommendation of an independent safety board.
BUSINESS
November 8, 1994 | From Times Staff and Wire Reports
Upjohn to Sell Seed Division: The Kalamazoo, Mich.-based prescription drug manufacturer said it will sell its vegetable seed division to Empresas La Moderna, a leading Mexican cigarette producer, for about $300 million. Upjohn's Asgrow Seed Co. is one of the world's top five seed companies, with sales of about $270 million last year. It develops and markets more than 1,000 varieties of vegetable seed.
BUSINESS
October 18, 1994 | From Times Wire Services
Citing reduced costs and record revenue generated by new products, Apple Computer Inc. on Monday posted fiscal fourth-quarter net income more than 42 times greater than a year ago. Apple said it earned $114.7 million in its fiscal fourth quarter, outdoing analysts' expectations. The company's profit for the quarter ended Sept. 30 amounted to 95 cents per share, sharply above the 65-cent consensus estimate on Wall Street. Last week, Apple said it expected to beat the Wall Street forecasts.
BUSINESS
October 17, 1994 | From Times Staff and Wire Reports
Cervical Cancer Screening Test: Upjohn Co. will begin distributing a new visual cervical cancer screening test Wednesday that was developed by Trylon Corp., a Torrance-based medical products company. The procedure, being marketed as Pap Plus Speculoscopy, is designed to be used in conjunction with the Pap smear laboratory test, which is used for early detection of cervical cancer. According to Trylon, its new procedure will provide immediate results in the doctor's office.
Los Angeles Times Articles
|